Edition:
United Kingdom

CTI Biopharma Corp (CTIC.OQ)

CTIC.OQ on NASDAQ Stock Exchange Capital Market

3.88USD
19 Apr 2018
Change (% chg)

$0.07 (+1.84%)
Prev Close
$3.81
Open
$3.80
Day's High
$3.90
Day's Low
$3.79
Volume
29,759
Avg. Vol
84,598
52-wk High
$4.51
52-wk Low
$2.46

Chart for

About

CTI BioPharma Corp. is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies covering a spectrum of blood-related cancers to patients and healthcare providers. The Company is primarily focused on commercializing PIXUVRI in select countries in the European Union, for... (more)

Overall

Beta: 0.62
Market Cap(Mil.): $140.98
Shares Outstanding(Mil.): 42.98
Dividend: --
Yield (%): --

Financials

  CTIC.OQ Industry Sector
P/E (TTM): -- 84.02 32.74
EPS (TTM): -1.80 -- --
ROI: -85.83 1.58 14.38
ROE: -127.14 2.41 16.07

BRIEF-Children's Hospital Of Philadelphia Foundation To Engage In Dialogue With Spark Therapeutics To Be Allowed To Designate At Least 1 Board Member

* CHILDREN'S HOSPITAL OF PHILADELPHIA FOUNDATION - TO ENGAGE IN DIALOGUE WITH SPARK THERAPEUTICS TO BE ALLOWED TO DESIGNATE AT LEAST 1 BOARD MEMBER

09 Mar 2018

BRIEF-CTI Biopharma Q4 Loss Per Share $0.33

* CTI BIOPHARMA REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

07 Mar 2018

BRIEF-Tempest Therapeutics Inc Says It Has Raised $25.2 Million In Equity Financing

* TEMPEST THERAPEUTICS, INC FILES TO SAY IT HAS RAISED $25.2 MILLION IN EQUITY FINANCING - SEC FILING​

01 Mar 2018

BRIEF-Growth Equity Opportunities Fund Reports 6.0 Pct Stake In CTI Biopharma

* GROWTH EQUITY OPPORTUNITIES FUND V LLC REPORTS 6.0 PERCENT STAKE IN CTI BIOPHARMA CORP AS OF FEB 8 - SEC FILING

20 Feb 2018

BRIEF-CTI BioPharma Prices Underwritten Public Offering Of $60 Million Of Common Stock

* CTI BIOPHARMA PRICES UNDERWRITTEN PUBLIC OFFERING OF $60 MILLION OF COMMON STOCK

09 Feb 2018

BRIEF-CTI Biopharma Announces Launch Of Follow-On Offering

* CTI BIOPHARMA CORP - INTENDS TO USE NET PROCEEDS OF OFFERING TO COMPLETE PAC203 CLINICAL TRIAL, COMPLETE REVIEW OF PACRITINIB MAA BY EMA, AMONG OTHERS Source text for Eikon:

05 Feb 2018

BRIEF-CTI Biopharma Provides Corporate And European Regulatory Update

* CTI BIOPHARMA PROVIDES CORPORATE AND EUROPEAN REGULATORY UPDATE

25 Jan 2018

Canada's Aurora Cannabis to buy rival to create world's most valuable weed firm

Canada's No. 2 marijuana producer Aurora Cannabis Inc has agreed to buy smaller rival CanniMed Therapeutics Inc for C$1.1 billion ($852 million) as companies jostle to benefit from the country's legalization of recreational marijuana use later this year. | Video

24 Jan 2018

Canadian cannabis firm Aurora in talks to buy both CanniMed and Newstrike -sources

TORONTO, Jan 19 Canadian marijuana producer Aurora Cannabis Inc is in talks with rivals CanniMed Therapeutics Inc and Newstrike Resources Ltd to acquire both companies in a friendly deal, people familiar with the situation told Reuters on Friday.

19 Jan 2018

Canadian cannabis firm CanniMed in talks with suitor Aurora

TORONTO Canadian cannabis producer CanniMed Therapeutics Inc said it has postponed a shareholder vote on its proposed takeover of Newstrike Resources Ltd to allow it to discuss a possible transaction with hostile suitor Aurora Cannabis Inc .

18 Jan 2018

Earnings vs. Estimates